Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GTX-B001 in Healthy Volunteers and Patients With Chronic Inducible Urticaria
NCT07181369Phase 1Recruiting
- Sponsor
- Granular Therapeutics
- Start
- Oct 2025
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic inducible urticaria (CIndU), Cold urticaria (CU) and symptomatic dermographism (4 arms), sponsored by Granular Therapeutics. Primary endpoint: Incidence and severity of adverse events. Started Oct 2025; status: recruiting.
02
Conditions
chronic inducible urticaria (CIndU)Cold urticaria (CU)symptomatic dermographism
Beyond the preview
Go deeper on NCT07181369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07181369.